Secondary analysis findings from the EMPACT-MI trial highlight empagliflozin's significant cardiovascular and kidney benefits when initiated soon after an acute myocardial infarction.

BACKGROUND: Fontan circulatory failure (FCF) is a chronic state in palliated single ventricle heart disease with high morbidity and mortality rates, including heart failure, multisystem end-organ ...

Bayer presents Kerendia data in heart failure with preserved and mildly reduced LVEF at ESC, sparking debate about how it may fit into treatment.

A gene therapy for heart failure being developed by Bayer’s AskBio unit has been granted fast-track status by the FDA.

Read current medical research on risk factors, causes and prevention of heart disease, strokes, and peripheral arterial disease. What new treatment options are under development?

Learn which heart problems can affect children, including congenital heart disease, arrhythmias, pericarditis, and Kawasaki disease. Learn about signs and treatment.